Wen Fury

This inventor holds 10 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wen Fury. Retrieved from https://idiyas.com/inventor/wen-fury

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 4 (Patent Applications = 10)

Average Co-Inventor Count = 2.7

ph-index = 4

Forward Citations = 27(Granted Patents)

Location History:

New York, NY (US) (2012 - 2023)
Tarrytown, NY (US) (2023)

Company Filing History:

10 out of 1,479

Regeneron Pharmaceuticals, Inc.

patents

Years Active: 2012-2025

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421512 - CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation (2025-09-23),

2. 12209238 - CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation (2025-01-28),

3. 11845931 - CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation (2023-12-19),

4. 11845930 - Methods and systems for CRISPR selection (2023-12-19),

5. 11594302 - High resolution allele identification (2023-02-28),

6. 10851158 - Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof (2020-12-01),

7. 10162933 - High resolution allele identification (2018-12-25),

8. 10083274 - Non-hypergeometric overlap probability (2018-09-25),

9. 10005834 - Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof (2018-06-26),

10. 8255167 - Non-hypergeometric overlap probability (2012-08-28),

Title: Innovations of Inventor Wen Fury

Introduction

Wen Fury is a prominent inventor based in New York, NY (US), known for his significant contributions to the field of biotechnology. He holds a total of 10 patents, showcasing his innovative approach to addressing complex biological challenges.

Latest Patents

Fury's latest patents include a CRISPR/Cas screening platform designed to identify genetic modifiers of tau seeding or aggregation. This includes the development of Cas-protein-ready tau biosensor cells and CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells. These inventions provide methods for making and using such cells to screen for genetic modifiers of tau seeding or aggregation. Additionally, he has developed reagents and methods for sensitizing these cells to tau seeding activity or tau aggregation, as well as for inducing tau aggregation.

Career Highlights

Wen Fury is currently employed at Regeneron Pharmaceuticals, Inc., where he continues to push the boundaries of scientific research and innovation. His work has been instrumental in advancing our understanding of tau-related diseases, which are critical in the context of neurodegenerative disorders.

Collaborations

Fury collaborates with talented individuals such as Yu Bai and Marine Prissette, who contribute to the innovative environment at Regeneron Pharmaceuticals. Their teamwork fosters a culture of creativity and scientific exploration.

Conclusion

Wen Fury's contributions to biotechnology through his patents and collaborative efforts highlight his role as a leading inventor in the field. His work not only advances scientific knowledge but also has the potential to impact therapeutic strategies for neurodegenerative diseases.

Profile summary based on public USPTO records.